The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Apricity Therapeutics; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Monopteros Therapeutics; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; xCures
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Apricity Therapeutics; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Clovis Oncology; Debiopharm Group; FOGPharma; Fount Therapeutics; Genentech; Lilly; Merck; Monopteros Therapeutics; Neon Therapeutics; Novartis; Oncoceutics; PIC Therapeutics; Pierre Fabre; Sanofi; Shattuck Labs; Strata Oncology; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; xCures
Research Funding - Novartis; Sanofi
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; Lunaphore Technologies; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Caroline Robert
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Keith T. Flaherty
No Relationships to Disclose
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; Highlight Therapeutics; ImaginAb; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; RAPT Therapeutics; Rgenix; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Steven Green
Employment - Novartis
Stock and Other Ownership Interests - Alcon; Novartis
 
Lali Sandalic
Employment - Novartis; PRA Health Sciences
Stock and Other Ownership Interests - Celldex; Chinook Therapeutics; Neoleukin Therapeutics; Novartis
 
Mike R. Lau
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Tonatiuh Romero
Employment - Novartis
 
Georgina V. Long
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; Specialised Therapeutics